Glaucoma clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
Sorry, not yet accepting patients
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
San Francisco, California
Our lead scientists for Glaucoma research studies include Julius Oatts, MD.